跳至主要内容
临床试验/JPRN-UMIN000021593
JPRN-UMIN000021593招募中2 期

Exploratory study for prevention of nausea and vomiting switching from Granisetron + Dexamethasone (Day1-3) + Aprepitant (Day1-3) to Palonosetron + Dexamethasone (Day1) in patients given moderately emetogenic chemotherapy - Study for switching from GRA+DEX+APR to PALO+DEX

Iwate Medical University, School of Medicine0 个研究点目标入组 30 人开始时间: 2016年3月24日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Serious or uncontrolled complication (e.g. ileus or pulmonary fibrosis, diabetes, heart failure, myocardial infarction, angina, kidney failure, liver failure, mental disorder, cerebrovascular disease, active gastroduodenal ulcer) 2) Symptomatic or clinically suspected brain metastasis 3) Convulsive disorder needs anticonvulsants 4) Ascites fluid or pleural effusion needs paracentesis 5) Pyloristenosis or intestinal obstruction 6) Evident anticipatory nausea and vomiting 7) Hypersensitivity for components of 5-HT3 receptor antagonist, NK1 receptor antagonist, dexamethasone 8) Pregnancy, lactation or who does not wish to contraception 9) Capability or intention of cooperating 10) Undesirable for the patient to enter the trial

研究者

发起方
Iwate Medical University, School of Medicine

相似试验